AEG-POWER-SOLUTIONS
AEG Power Solutions (FWB:3W9K), a global provider of power electronic systems and solutions for industrial power supplies and renewable energy applications, announces the 20th anniversary of its Transokraft inverter.
The latest version of the system was re-launched in 2012 and includes new software-free features; this absence of embedded software prevents any risk of digital instability, thus providing the highest level of security and reliability for the equipment.
For two decades, Transokraft inverters have helped to secure the power supply for critical infrastructure and processes around the globe. Transokraft was designed to comply with the most stringent standards of nuclear power generation applications, and the inverters are certified for quality insurance accordingly (KTA1401). They rank first in class of their category in qualification tests where they have proven their high levels of resistance to seismic and climatic shocks, as well as their functional capacity under electromagnetic disturbances in EMC tests.
Transokraft equips many of the world’s nuclear power plants, including Heysham in the UK, Oskarshamn in Sweden, Olkiluoto in Finland, Pickering in Canada, Atucha in Argentina, Gösgen in Switzerland, Taishan in China.
“Twenty years ago, we introduced Transokraft to help secure the power supply of nuclear power plants and other critical applications – and customers immediately recognised its reliability and ability to help provide a dependable, safe solution even in the most challenging operational conditions,” says Rudolf Poeppelbaum, Sales Manager Power Generation at AEG Power Solutions. “Combined with AEG PS’ service expertise and unrivalled technical support, we expect Transokraft to carry on serving our customers for decades to come.”
Transokraft is part of an extensive range of products designed by AEG Power Solutions to meet power generation industry needs and the specific requirements of nuclear applications. Devices in the range include the Profitec S and SN1 battery chargers, as well as switch mode power supply modules. The portfolio of available products enables customers to benefit from a single certified source, complying with the same standards. All systems can be fully customized.
As proven by their track record, the rugged and highly reliable technology of this range results in systems that can be supported for a minimum of 20 years. The consistency in design minimizes spare part requirements and provides operational simplicity.
No. No. No.
About AEG Power Solutions
AEG Power Solutions (AEG PS) Group is a global provider of power electronics systems and solutions for all industrial and demanding commercial power requirements offering one of the most comprehensive product and service portfolios in the area of uninterruptible power supply and power management. Thanks to its distinctive expertise bridging both AC and DC power technologies and spanning the worlds of both conventional and renewable energy, the company creates innovative solutions for next generation distributed power generation.
AEG Power Solutions Group is the sole subsidiary of the holding company 3W Power S.A. (WKN A114Z9) / ISINLU1072910919), based in Luxembourg. The Group is headquartered in Zwanenburg in the Netherlands. The shares of 3W Power are admitted to trading on Frankfurt Stock Exchange (ticker symbol: 3W9K).
For more information, visit www.aegps.com
This communication does not constitute an offer or the solicitation
of an offer to buy, sell or exchange any securities of 3W Power. This
communication contains forward-looking statements which include, inter
alia, statements expressing our expectations, intentions, projections,
estimates, and assumptions. These forward-looking statements are based
on the reasonable evaluation and opinion of the management but are
subject to risks and uncertainties which are beyond the control of 3W
Power and, as a general rule, difficult to predict. The management and
the company cannot and do not, under any circumstances, guarantee future
results or performance of 3W Power and the actual results of 3W Power
may materially differ from the information expressed or implied in the
forward-looking statements. As a result, investors are cautioned against
relying on the forward-looking statements contained herein as a basis
for their investment decisions regarding 3W Power.
3W Power
undertakes no obligation to update or revise any forward-looking
statement contained herein.
Photos/Multimedia Gallery Available: http://www.businesswire.com/multimedia/home/20141126005228/en/
Contact:
Press contact:
Ute von Cranach, Phone.: +49 2902 763 256
Mobile:
+49 170 574 9094
Marketing Communications
AEG Power Solutions
Email:
ute.voncranach@aegps.com
or
Agency
contact :
Gerlinde Knöpfle, Phone: +49 89 6491 3634-12
Mobile:
+49 160 9512 7238
embedded PR
Müllerstr. 44 Rgb., 80469 München
Email:
gk@embedded-pr.de
Link:
Information om Business Wire
Følg pressemeddelelser fra Business Wire
Skriv dig op her, og modtag pressemeddelelser på e-mail. Indtast din e-mail, klik på abonner, og følg instruktionerne i den udsendte e-mail.
Flere pressemeddelelser fra Business Wire
Prilenia Enters into a Collaboration and License Agreement with Ferrer for the Commercialization and Co-Development of Pridopidine in Europe and Other Select Markets28.4.2025 07:02:00 CEST | Press release
-- Total deal size of approximately €500 million, including approximately €125 million in upfront and near-term milestones ---- Ferrer to commercialize pridopidine in Europe and other select markets; Prilenia retains full commercialization and development rights to pridopidine in North America, Japan and Asia Pacific ---- Co-development agreement in the territory supports further expansion of pridopidine in Huntington’s disease, amyotrophic lateral sclerosis and future indications ---- Pridopidine for Huntington’s disease is currently under review by the European Medicines Agency (EMA) with a CHMP opinion expected in the second half of 2025 -- Prilenia Therapeutics B.V., a biopharmaceutical company driven by an unwavering commitment to scientific excellence and accelerating progress for people affected by Huntington’s disease (HD) and amyotrophic lateral sclerosis (ALS), today announced that it has entered into a collaboration and license agreement with Ferrer for the commercialization
Ferrer Enters Into a Collaboration and License Agreement With Prilenia for the Commercialization and Co-Development of Pridopidine28.4.2025 07:00:00 CEST | Press release
Ferrer, an international B Corp pharmaceutical company with an increasing focus on rare neurological diseases, and Prilenia Therapeutics B.V.,a clinical-stage biotech company, have announced the signing of a strategic co-development and license agreement in which Ferrer obtains the rights to develop, manufacture and commercialize Pridopidine in the European Region, the Middle East and North African Region, the Southern African Region, the Central and South American Region, and the Commonwealth of Independent States Region. Pridopidine, a potent and highly selective, orally administered sigma-1 receptor agonist, designed to regulate key neuroprotective mechanisms that are often impaired in neurodegenerative diseases, is a promising candidate for the treatment of Huntington’s Disease (HD), a rare inherited neurodegenerative disease, with a high unmet medical need1. It has been studied in more than 1,700 people and long-term safety data of up to 7 years duration are available from previou
Innorna Announces FDA Rare Pediatric Disease and Orphan Drug Designations Granted to IN013 for Treatment of Wilson Disease27.4.2025 11:36:00 CEST | Press release
Innorna, a clinical-stage biotechnology company revolutionizing mRNA therapeutics with its innovative lipid nanoparticle (LNP) delivery technology, today announced the U.S. Food and Drug Administration (FDA) has granted both Rare Pediatric Disease Designation (RPDD) and Orphan Drug Designation (ODD) to its investigational mRNA therapy, IN013, for treating Wilson Disease (WD). This dual achievement accelerates the clinical development of IN013, advancing Innorna’s mission to deliver transformative therapies for WD patients. About FDA Designations The Rare Pediatric Disease Designation (RPDD) incentivizes therapies for serious or life-threatening diseases affecting fewer than 200,000 U.S. patients, primarily those aged 18 or younger. Sponsors may qualify for a Priority Review Voucher (PRV) upon approval to expedite FDA review of a subsequent drug application. The Orphan Drug Designation (ODD) supports therapies targeting rare diseases (affecting fewer than 200,000 U.S. patients) by provi
Everen Specialty Appoints Carla Greaves Chief Underwriting Officer25.4.2025 19:00:00 CEST | Press release
Everen Specialty, a Bermuda-based (re)insurer for energy markets worldwide, today announced the appointment of Carla Greaves as its new Chief Underwriting Officer (CUO). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250425273777/en/ Carla Greaves Ms. Greaves will join the Executive Leadership Team of the Everen Group, based in the Bermuda office, later this year. She succeeds Jane Peterson, Interim CUO, who will continue in a consultancy capacity to facilitate the transition. With more than 30 years of underwriting and leadership experience in the (re)insurance industry, Ms. Greaves brings a wealth of expertise and a proven track record of success in the Casualty market where she is recognized for building high-performing teams, driving profitable growth, and successfully navigating complex market environments. Prior to joining Everen Specialty, Ms. Greaves held increasingly senior leadership positions, most recently servin
Incyte to Highlight Early-Stage Oncology Data at American Association for Cancer Research Annual Meeting 202525.4.2025 14:00:00 CEST | Press release
Incyte (Nasdaq:INCY) today announced that the Company will present new early-stage data from its oncology portfolio at the American Association of Cancer Research (AACR) Annual Meeting 2025 in Chicago, IL, from April 25–30. “At AACR we will be presenting data from early-stage programs across our oncology portfolio, including for patients with myeloproliferative neoplasms, ovarian cancer and other solid tumors,” said Pablo J. Cagnoni, M.D., President and Head of Research and Development, Incyte. “These data will guide our approach as we advance our pipeline and seek to transform the treatment landscape for patients with cancer and myeloproliferative neoplasms.” Abstracts accepted for presentation at AACR include: Mini Symposium INCB177054 INCB177054: A Novel, Potent, Orally Bioavailable DGKα/ζ Dual Inhibitor Enhances T-Cell Function and Demonstrates Potent Antitumor Activity (Session Title: Novel Antitumor Agents. April 28, 4:50 p.m. – 5:05 p.m. ET (3:50 p.m. – 4:05 p.m. CT). Abstract #
I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter samt finde vores kontaktoplysninger.
Besøg vores nyhedsrum